Skip to main content
Retour
Watch Compare

PharmaCyte Biotech, Inc.

Qualité des données : 100%
PMCB
Nasdaq Manufacturing Chemicals
0,68 €
▲ 0,00 € (0,31%)
Cap. Boursière: 7,34 M
Prix
0,68 €
Cap. Boursière
7,34 M
Fourchette du Jour
0,67 € — 0,72 €
Fourchette 52 Semaines
0,63 € — 1,51 €
Volume
69 145
Ouverture 0,72 €
Moyenne 50J / 200J
0,73 €
6,82% below
Moyenne 50J / 200J
0,89 €
23,46% below

Quick Summary

Points Clés

Earnings grew 9084,98% over the past year
Negative free cash flow of -4,80 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)9084,98%
FCF Growth (3Y)N/A

Qualité

Return on Equity
-8,95%
Au-dessus de la moyenne du secteur (-53,47%)
ROIC-7,83%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio12,33
Interest CoverageN/A

Valorisation

PE (TTM)
-2,24
En dessous de la moyenne du secteur (-1,47)
P/B Ratio0,19
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -2,2 -1,5
P/B 0,2 1,6
ROE % -9,0 -53,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) 9084,98% Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -3,28 M
ROE -8,95% ROA -5,87%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -4,80 M
ROIC -7,83% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 12,33
Interest Coverage N/A Asset Turnover 0,00
Working Capital 19,02 M Tangible Book Value 36,56 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2,24 Forward P/E N/A
P/B Ratio 0,19 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -65,43%
Market Cap 7,34 M Enterprise Value -12,83 M
Per Share
EPS (Diluted TTM) -0,89 Revenue / Share 0,00
FCF / Share -0,45 OCF / Share -0,45
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 146,29%
SBC-Adj. FCF -5,77 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 0,0
Net Income 30,66 M 333 763,0 -4,32 M -4,24 M -3,55 M
EPS (Diluted) 3,19 -1,80 -0,22 -0,27 —
Gross Profit — — — — —
Operating Income -4,38 M -8,52 M -6,46 M -4,39 M -3,62 M
EBITDA — — — — —
R&D Expenses 438 416,0 407 431,0 468 536,0 690 937,0 916 249,0
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — 0,0 509,0 3 046,0
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 55,17 M 59,90 M 73,28 M 90,62 M 7,40 M
Total Liabilities 3,28 M 20,39 M 586 581,0 704 370,0 724 778,0
Shareholders' Equity 51,89 M 27,65 M 72,69 M 89,92 M 6,68 M
Total Debt — — — — —
Cash & Equivalents 15,17 M 50,18 M 68,04 M — —
Current Assets 22,38 M 50,44 M 68,15 M 85,49 M 2,28 M
Current Liabilities 2,91 M 7,42 M 586 581,0 704 370,0 724 778,0